The Anticoagulant Therapy with Bivalirudin to Assist in the Performance of Percutaneous Coronary Intervention in Patients with Heparin-Induced Thrombocytopenia (ATBAT) Study: Main Results

Journal of Invasive Cardiology

Volumn 15, Issue 11, 2003, Pages 611-616

  Mahaffey, Kenneth W ^a   Lewis, Bruce E ^b   Wildermann, Nancy M ^a   Berkowitz, Scott D ^a,c   Oliverio, Renee M ^a   Turco, Mark A ^d   Shalev, Yoseph ^e   Lee, Peter Ver ^f   Traverse, Jay H ^g   Rodriguez, A Ralph ^h   Ohman, E Magnus ⁱ   Harrington, Robert A ^a   Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

^d WASHINGTON ADVENTIST HOSPITAL   (United States)

^e AURORA SINAI MEDICAL CENTER   (United States)

^f EASTERN MAINE MEDICAL CENTER   (United States)

^g ABBOTT NORTHWESTERN HOSPITAL   (United States)

^h FLORIDA HOSPITAL   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bivalirudin; Direct thrombin inhibitor; Heparin induced thrombocytopenia; PCI

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; DRUG DERIVATIVE; EFEGATRAN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TICLOPIDINE;

ADULT; AGED; ANEMIA; ANTICOAGULATION; ARTERY SPASM; ARTICLE; ASYSTOLE; BLEEDING; BLOOD FLOWMETRY; BRACHIALGIA; BRAIN HEMORRHAGE; BYPASS SURGERY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DEATH; DEVELOPING COUNTRY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; EMERGENCY SURGERY; FEMALE; HEART ARREST; HEART INFARCTION; HEMATOMA; HEPARINIZATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPOTENSION; IATROGENIC DISEASE; ISCHEMIC HEART DISEASE; LIMB PAIN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; NAUSEA; PERICARDIAL EFFUSION; PROSPECTIVE STUDY; Q WAVE; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; SAFETY; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VOMITING;

AGED; ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; FEMALE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 10744222644     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Spencer FA. Heparin-induced thrombocytopenia: Patient profiles and clinical manifestations. J Thromb Thrombol 2000;10:S21-S55.
2. Walenga JM, Jeske WP, Messmore HL. Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. J Thromb Thrombol 2000;10:S13-S20.
3. Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;332:1374-1376.
4. Bates SM, Weitz JI. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hirudin. Am J Cardiol 1998;82:12P-18P.
5. Maraganore JM. Preclinical and clinical studies on Hirulog: A potent and specific direct thrombin inhibitor. In: Claeson G, Scully MF, Kakkar VV, Deadman J, (eds). Design of Synthetic Inhibitors of Thrombin. Plenum Prexs, New York: 1993: pp. 227-236.
6. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302.
7. Kong DF, Topol EJ, Bittl JA, et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999;100:2049-2053.
8. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863.
9. Campbell KR, Mahaffey KW, Lewis BE, et al. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. J Invas Cardiol 2000;12:14F-19F.
10. Mahaffey KW. Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Curr Cardiol Rep 2001;3:362-370.
11. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002;143:847-853.
12. Lincoff AM, Bittl JA, Kleiman NS, et al. The REPLACE 1 trial: A pilot study of bivalirudin versus heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade (Abstr). J Am Coll Cardiol 2002;39:16A.
13. Topol EJ, Bonan R, Jewitt D, et al. Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
14. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
15. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: Final report reanalysis of the Hirulog Angioplasty Study. Am Heart J 2001;142:952-959.
16. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
17. Matthai WH Jr. Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. Semin Thromb Hemost 1999;25:57-60.
18. Lewis BE, Matthai WH, Cohen M, et al., for the ARG-216/310/311 Study Investigators. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Intervent 2002;57:177-184.
19. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999;99:73-80.
20. Greinacher A, Janssens U, Berg G, et al., for the HAT Study Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999;100:587-593.
21. OASIS Investigators. Effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study. Circulation 1997;96:769-777.
22. The OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial. Lancet 1999;353:429-438.